INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)today announces that a Phase I trial sponsored by Bristol-Myers Squibb was published on the NIH website ClinicalTrials.gov for IPH2102/BMS-986015 and is currently recruiting

Transparency directive : regulatory news

30/10/2012 07:15

PRESS RELEASE

                FIRST CLINICAL TRIAL WITH IPH2102/BMS-986015
                SPONSORED BY BRISTOL-MYERS SQUIBB ANNOUNCED

* A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1
   Antibody in Patients With Advanced Solid Tumors

Marseilles, France, October 30, 2012

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the
innate immunity company developing first-in-class drugs for cancer and
inflammatory diseases, today announces that a Phase I trial sponsored by
Bristol-Myers Squibb was published on the NIH website ClinicalTrials.gov for
IPH2102/BMS-986015 and is currently recruiting*.

Marcel Rozencweig, Chief Medical Officer of Innate Pharma, said:
"IPH2102/BMS-986015 will be tested in a variety of solid tumors, in
combination with anti-PD-1 which has shown promising single agent results in
Phase I/II trials."

About the Phase I trial with IPH2102/BMS-986015 in combination with Anti-PD-1
(BMS-936558) in solid tumors

The purpose of this Phase I open label study is to determine whether the
combination of IPH2102/BMS-986015 and BMS-936558 is safe and provide
preliminary information on the clinical activity of the combination.

The primary outcome will be safety. Secondary outcomes will include a
preliminary assessment of efficacy, as measured by tumor assessment. It will
be conducted in two parts - dose escalation and cohort expansion - and is
expected to enroll approximately 150 patients, with up to 48 patients in dose
escalation and up to 96 patients in cohort expansion. During dose escalation,
patients with any advanced tumor type (with the exception of primary central
system tumors and hematologic malignancies) will be eligible to enroll. During
cohort expansion, tumor type will be restricted to the following advanced
malignancies: non-small cell lung cancer - squamous and non-squamous
histology, Renal Cell Carcinoma, Melanoma, Colorectal Cancer and Serous
Ovarian Carcinoma.

About IPH2102/BMS-986015

IPH2102/BMS-986015 is a fully human monoclonal antibody blocking interaction
between Killercell immunoglobulin-like receptors (KIR) on NK cells with their
ligands. Blocking these receptors facilitates activation of NK cells and,
potentially, destruction of tumor cells by the latter.

IPH2102/BMS-986015 is licensed to Bristol-Myers Squibb Company (NYSE:BMY). As
part of the agreement between Innate Pharma and Bristol-Myers Squibb,
Bristol-Myers Squibb holds exclusive worldwide rights to develop, manufacture
and commercialize IPH2102/BMS-986015 and related compounds blocking KIR
receptors, for all indications. Under the agreement, Innate Pharma will
conduct the development of IPH2102/BMS-986015 through Phase II in acute
myeloid leukemia. A randomized, double-blind, placebo-controlled Phase II
trial assessing IPH2 102/BMS-9860 15 is about to be initiated in elderly
patients with acute myeloid leukemia in a maintenance setting.

* http://www.clinicaltrials.gov/ct2/show/NCT01714739?term=BMS-986015&rank=1

About Anti-PD-1 (BMS-936558)

Anti-PD-1 is a fully-human antibody that targets the inhibitory receptor
expressed on activated T-cells called PD-1 or programmed death-1().

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 81 employees as at
June 30, 2012.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code                       FR0010331421
Ticker code                     IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http ://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:
Innate Pharma                              ATCG Press
Laure-Hélène Mercier                       Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87                Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com                mb@atcg-partners.com

() For more information, please refer to:
http://news.bms.com/press-release/financial-news/investigational-anti-pd-1-
immunotherapy-bms-936558-showed-clinical-acti

121030 Bristol-Myers Squibb Phase I trial combo PD-1

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)today announces that a Phase I trial sponsored by Bristol-Myers Squibb was published on the NIH website ClinicalTrials.gov for IPH2102/BMS-986015 and is currently recruiting

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories